Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

MRD-guided maintenance after transplant in FLT3-ITD acute myeloid leukemia: gilteritinib versus sorafenib

Phase 3 trial of MRD-guided maintenance after allogeneic transplant. The registry primary outcome is measurable residual disease recurrence-free survival. ClinicalTrials.gov lists the study as recruiting.

The First Affiliated Hospital of Soochow University